retatrutide phase 2 trial obesity triple agonist First-in-Class 'Triple-G'! Retatrutide, a first-in Today, we shared new data

By Anna Watson PharmD Candidate (P4) For questions, e-mail [email protected] References: 2 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

doi: 10.3389/fimmu.2017.01734 9 NagaeKUchiHMorino-KogaSTanakaYOdaMFurueM

GLP-1s can also cause gastrointestinal issues such as nausea and vomiting, which may cause some people to discontinue use due to side effects before achieving their weight-loss goals

PlexusDx offers tirzepatide injection and GLP-Squared combinations that activate additional appetite pathways, often producing better results for non-responders

Inject at 12 oclock one week, 3 oclock the next, and so on

287 , C1238C1245 (2004)